vimarsana.com
Home
Live Updates
Tiziana Life Sciences Ltd.: Tiziana Life Sciences Hosting Ke
Tiziana Life Sciences Ltd.: Tiziana Life Sciences Hosting Ke
Tiziana Life Sciences Ltd.: Tiziana Life Sciences Hosting Key Opinion Leader Virtual Event to Discuss the Intranasal Delivery of Foralumab in Multiple Sclerosis
Monday, March 14th @ 11 am ET, registration details belowNEW YORK, March 11, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling
Related Keywords
Boston ,
Massachusetts ,
United States ,
India ,
Toronto ,
Ontario ,
Canada ,
Philadelphia ,
Pennsylvania ,
Irina Koffler ,
Lawrence Steinman ,
Neuromyelitis Optica ,
Robertl Kroc ,
Howardl Weiner ,
Tarun Singhal ,
Howard Weiner ,
Hana Malik ,
Tanuja Chitnis ,
Brigham Pediatric Ms Center ,
Professor Of Neurology At Harvard Medical School ,
Imaging Program In Neurologic Diseases ,
Tiziana Life Sciences Ltd Nasdaq ,
Founder Of The Partners Multiple Sclerosis Center ,
Stanford University Interdepartmental Program In Immunology ,
Neurological Sciences ,
Harvard Medical School ,
University Of Toronto Medical School ,
Tiziana Life Sciences ,
International Pediatric Ms Workgroup ,
Tiziana Life Sciences Ltd ,
India Institute Of Medical Sciences ,
Ann Romney Center ,
Business Development ,
Life Sciences Ltd ,
Key Opinion Leader ,
Clinical Update ,
Multiple Sclerosis ,
Landmark Study ,
Massachusetts General Hospital ,
Stanford Medicine ,
Secondary Progressive Multiple Sclerosispositive ,
Partners Multiple Sclerosis Center ,
Neurologic Diseases ,
Show Science ,
Medical School ,
Neurology Endowed ,
Mass General Brigham Pediatric ,
Mass General Hospital ,
Toronto Medical School ,
Harvard Medical ,
International Pediatric ,
Assistant Professor ,
All India Institute ,
Medical Sciences ,
Norepinephrine Transporter ,
Stanford University Interdepartmental Program ,
Life Sciences ,
Investor Relations ,
Tiziana ,
Life ,
Ciences ,
Posting ,
Opinion ,
Leader ,
Irtual ,
Event ,
Iscuss ,
Intranasal ,
Delivery ,
Foralumab ,
Multiple ,
Clerosis ,